Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria
View original at globenewswire.comPress Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria Approval in CSU for chi…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Dupixent provides a first-of-its kind approach to addressing chronic spontaneous urticaria in young children by inhibiting signaling of IL-4 and IL-13, two key drivers of type 2 inflammation
60% confidenceIL-4 and IL-13 are two of the key and central drivers of type 2 inflammation that plays a major role in multiple related and often co-morbid diseases
60% confidencePrevious treatment options for young children with chronic spontaneous urticaria left many patients with uncontrolled disease where the unpredictable appearance of itch and hives continued to disrupt their daily lives
60% confidenceDupixent has the potential to become the new standard of care for young children with CSU who remain symptomatic despite other available treatments
60% confidenceThis approval demonstrates our commitment to extending the value of Dupixent to all who may benefit, including young children
60% confidenceDupixent is the most widely used innovative branded antibody medicine in the world
60% confidenceThis fourth approval for young children with chronic diseases driven in part by type 2 inflammation brings Dupixent's proven efficacy and long-term safety profile to yet another vulnerable population in need
60% confidence